ORMP - オラメド・ファ―マシュ―ティカルズ （Oramed Pharmaceuticals Inc.）

China is soon likely to become the world’s first country with oral insulin availability. After successfully completing Phase III trials of oral insulin, China’s Hefei Tianhui Biotechnology (HTIT) submitted a marketing authorisation application (MAA) to the country’s National Medical Products Administration. Oramed’s US-based ORA-D-013-1 Phase III trial for the treatment of Type 2 diabetes showed significant lowering of A1C levels, which reflects the average blood sugar level for the past two to three months. HTIT is a strategic partner of Israeli company Oramed Pharmaceuticals. “Oral insulin is a paradigm shift from the traditional injectable insulin market. Therefore, there would be a lot of opportunities and challenges in the commercialisation of oral insulins,” said Prashant Khadayate, Pharma Analyst at GlobalData, in a statement. “Even though insulin delivery through injections has improved significantly for patients, compliance is always an issue for injectable forms of insulin. Hence, oral insulin will always be preferred, potentially reducing the discomfort associated with injections and thereby, improving overall compliance, provided it is equally effective in terms of efficacy and safety.

https://www.investing.com/news/pro/oramed-pharmaceuticals-inc-receives-investment-bank-analyst-rating-update-3084634

Fighting either type of diabetes is a challenge that can follow some around for their entire lives. That’s why news out of healthcare stock Oramed …

Gainers NeoGames S.A. (NASDAQ: NGMS ) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash. 1847 Holdings LLC (NASDAQ: EFSH ) gained 64.5% to $0.9050 after the company reported a 27.6% increase in revenue to $15.4 million and achieved profitability for the first quarter. Harbor Custom Development, Inc. (NASDAQ: HCDI ) surged 49.5% to $8.97 following first-quarter results. WiSA Technologies, Inc. (NASDAQ: WISA ) rose 47.4% to $2.33 after the company signed a Letter of Intent to acquire Comhear. WiSA expects acquisition to be accretive beginning in the fourth quarter and sees FY24 revenue of $10 million to $15 million. Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) gained 39% to $3.94 as the company said that its Chinese partner, HTIT, has successfully completed a Phase 3 oral insulin clinical trial and submitted a marketing authorization application in China. LM Funding America, Inc. (NASDAQ: LMFA ) jumped 34% to $0.9816 following better-than-expected results for the first quarter.

Oramed Pharmaceuticals Inc (NASDAQ: ORMP ) shares are trading higher after its partner completed Phase 3 trials of oral insulin in type 2 diabetes in China under a differentiated study protocol . Hefei Tianhui Biotechnology Co Ltd , a strategic partner of Oramed, is moving toward regulatory approval and has submitted the data to the National Medical Products Administration. Oramed has recently … Full story available on Benzinga.com

China is soon likely to become the world’s first country with oral insulin availability. After successfully completing Phase III trials of oral insulin, China’s Hefei Tianhui Biotechnology (HTIT) submitted a marketing authorisation application (MAA) to the country’s National Medical Products Administration. Oramed’s US-based ORA-D-013-1 Phase III trial for the treatment of Type 2 diabetes showed significant lowering of A1C levels, which reflects the average blood sugar level for the past two to three months. HTIT is a strategic partner of Israeli company Oramed Pharmaceuticals. “Oral insulin is a paradigm shift from the traditional injectable insulin market. Therefore, there would be a lot of opportunities and challenges in the commercialisation of oral insulins,” said Prashant Khadayate, Pharma Analyst at GlobalData, in a statement. “Even though insulin delivery through injections has improved significantly for patients, compliance is always an issue for injectable forms of insulin. Hence, oral insulin will always be preferred, potentially reducing the discomfort associated with injections and thereby, improving overall compliance, provided it is equally effective in terms of efficacy and safety.

https://www.investing.com/news/pro/oramed-pharmaceuticals-inc-receives-investment-bank-analyst-rating-update-3084634

Fighting either type of diabetes is a challenge that can follow some around for their entire lives. That’s why news out of healthcare stock Oramed …

Gainers NeoGames S.A. (NASDAQ: NGMS ) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash. 1847 Holdings LLC (NASDAQ: EFSH ) gained 64.5% to $0.9050 after the company reported a 27.6% increase in revenue to $15.4 million and achieved profitability for the first quarter. Harbor Custom Development, Inc. (NASDAQ: HCDI ) surged 49.5% to $8.97 following first-quarter results. WiSA Technologies, Inc. (NASDAQ: WISA ) rose 47.4% to $2.33 after the company signed a Letter of Intent to acquire Comhear. WiSA expects acquisition to be accretive beginning in the fourth quarter and sees FY24 revenue of $10 million to $15 million. Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) gained 39% to $3.94 as the company said that its Chinese partner, HTIT, has successfully completed a Phase 3 oral insulin clinical trial and submitted a marketing authorization application in China. LM Funding America, Inc. (NASDAQ: LMFA ) jumped 34% to $0.9816 following better-than-expected results for the first quarter.

Oramed Pharmaceuticals Inc (NASDAQ: ORMP ) shares are trading higher after its partner completed Phase 3 trials of oral insulin in type 2 diabetes in China under a differentiated study protocol . Hefei Tianhui Biotechnology Co Ltd , a strategic partner of Oramed, is moving toward regulatory approval and has submitted the data to the National Medical Products Administration. Oramed has recently … Full story available on Benzinga.com

A share of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) closed at $2.13 per share on Thursday, down from $2.20 day before. While Oramed Pharmaceuticals Inc. has underperformed by -3.18%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ORMP fell by -78.48%, with highs and lows ranging from $13.73 […]

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Wondrous stocks: BP p.l.c. (NYSE:BP 1.93%), Oramed Pharmaceuticals Inc. (NASDAQ:ORMP -0.95%) appeared first on Stocks Equity .

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Wondrous stocks: Oramed Pharmaceuticals Inc. (NASDAQ:ORMP -1.36%), Ouster, Inc. (NYSE:OUST -1.29%) appeared first on Stocks Equity .

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) shares, rose in value on Wednesday, 02/08/23, with the stock price up by 1.46% to the previous day’s close as strong demand from buyers drove the stock to $2.08. Actively observing the price movement in the last trading, the stock closed the session at $2.05, falling within a range of $2.025 … Exploring Growth Opportunities In Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) Read More »

ORMP has seen its SMA50 which is now -70.74%. In looking the SMA 200 we see that the stock has seen a -69.77%. DPRO has seen its SMA50 which is … The post Astonishing stocks: Oramed Pharmaceuticals Inc. (NASDAQ:ORMP -1.44%), Draganfly Inc. (NASDAQ:DPRO -12.77%) appeared first on Stocks Equity .